Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1632 1633 1634 1638
This examiner grants 24% of resolved cases
Alexandra F. Connors has managed 113 resolved cases in Tech Center 1600. Her work in Art Unit 1631 is defined by an allowance rate of 23.9 percent. This figure indicates a rigorous examination process where a minority of applications reach a grant. Practitioners should prepare for a challenging prosecution environment given this 23.9 percent success rate.
The median days to allowance is 1549, which represents a significant investment of time for any application that successfully navigates the process. This timeframe of 1549 days is a vital piece of information for managing the expectations of stakeholders regarding the speed of patent issuance.
The interview lift for this examiner is 45.4 percent. This is a substantial increase relative to the base allowance rate of 23.9 percent. The data suggests that engaging in an interview is a highly effective strategy, as the 45.4 percent lift indicates a much higher likelihood of overcoming rejections through direct communication. This metric provides a strong justification for the additional effort of scheduling a meeting with the examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17635047 | TARGETING OF THE CYTOSKELETON AS A THERAPEUTIC APPROACH FOR NEURODEGENERATIVE DISEASE | Final Rejection | University of Massachusetts |
| 18830890 | MANUFACTURING METHOD OF MIXED POWDER, MIXED POWDER, POWDER, AND POWDER MEDIUM | Non-Final OA | FUJIFILM Corporation |
| 18320499 | BIOMATERIALS CONTAINING UMBILICAL CORD-DERIVED STEM CELLS | Non-Final OA | GLOBUS MEDICAL, INC. |
| 19361681 | METHODS AND COMPOSITIONS FOR PRODUCING GRANULOSA-LIKE CELLS | Final Rejection | President and Fellows of Harvard College |
| 18029875 | NOVEL NR1 ES-DERIVED NEURAL STEM CELLS HAVING A NORMAL KARYOTYPE AND USES THEREOF | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 16314471 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ORGAN FIBROSIS | Non-Final OA | TOHOKU UNIVERSITY |
| 18223434 | VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17995687 | CONDITIONING REGIMENS FOR IN VIVO GENE THERAPY | Non-Final OA | University of Washington |
| 17224831 | METHODS OF TREATING INFLAMMATION | Non-Final OA | University of South Florida |
| 18044288 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | Final Rejection | University Health Network |
| 18043095 | ALGINATE-COATED MESENCHYMAL STROMAL AND PROGENITOR CELLS AND METHODS FOR USING THE SAME | Final Rejection | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 16971995 | METHODS AND COMPOSITIONS COMPRISING CART AND A SMAC MIMETIC | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 16081346 | THERAPY FOR FRONTOTEMPORAL DEMENTIA | Final Rejection | The Trustees of the University of Pennsylvania |
| 18454646 | FAT-ASSOCIATED LYMPHOID CLUSTERS AS SITES FOR TRANSPLANTATION, TISSUE REGENERATION, ORGANOGENESIS AND FUNCTION FOR MULTIPLE TISSUES | Final Rejection | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18850414 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | Non-Final OA | ASKBIO INC. |
| 17631322 | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR | Non-Final OA | Translate Bio, Inc. |
| 18889101 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | Non-Final OA | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES |
| 16968504 | PROMOTING AND PROTECTING FUNCTIONAL BETA CELL MASS BY SYNTAXIN 4 ENRICHMENT | Non-Final OA | CITY OF HOPE |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 17906150 | METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE II | Final Rejection | Mesoblast International Sárl |
| 16328853 | Provision of a Therapeutically Active Cell Product | Non-Final OA | PDI Pharm Development International AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy